Tag: China

ROCKVILLE, Md. and SUZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced the appointments of Veet Misra, Ph.D., as the Company’s Chief Financial Officer, and Mr. Eric Huang, as Senior Vice President of Global Corporate Development and Finance. Both Dr. Misra and Mr. Huang will report directly to Dajun Yang, M.D., Ph.D., the Company’s Chairman & Chief Executive Officer.

Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology

Ningde, Fujian, China, July 07, 2025 (GLOBE NEWSWIRE) -- Oriental Rise Holdings Limited (Nasdaq: ORIS) (“Oriental Rise” or the “Company”), an integrated supplier of white- and black-tea products in mainland China, today announced that on June 30, 2025 it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid-price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

The notification resulted from the fact that the closing bid price of the Company’s ordinary shares was below US $1.00 per share for 30 consecutive business days, from May 15, 2025 to June 27, 2025. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notice has no immediate effect on the listing of the Company’s ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “ORIS.”

Under Nasdaq Listing Rule 5810(c)(3)(A), Oriental Rise has a 180-calendar-day compliance period, ending on December 29, 2025 (the “Compliance Period”), to regain compliance with the minimum bid-price rule. If at any time during the Compliance Period the closing bid price of the Company’s ordinary shares is at least US $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.

If the Company does not regain compliance within the initial Compliance Period, it may be eligible for an additional 180-calendar-day grace period, provided that it meets all other continued-listing criteria for the Nasdaq Capital Market (except the bid-price requirement) and notifies Nasdaq of its intention to cure the deficiency, which may include implementing a reverse stock split if necessary.

Oriental Rise is actively monitoring the bid price of its ordinary shares and is evaluating all available options to regain compliance with Nasdaq’s requirements. The Company remains committed to delivering value to its shareholders and maintaining its listing on Nasdaq.